Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The combination therapy is indicated as an adjunct to diet and exercise to improve glycaemic control in adults where treatment with both medicines is appropriate. According to IQVIA data, the product has an estimated US market size of $514 million for the twelve months ending February 2026. Aurobindo is eligible for 180 days of shared generic exclusivity as one of the first applicants.
As of March 31, 2026, the company had a total of 579 ANDA approvals from the USFDA, including 554 final approvals and 25 tentative approvals.
Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company’s consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.
Shares of Aurobindo Pharma shed 0.76% to close at Rs 1,329.60 on the BSE.
These products will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company and will be launched immediately.
The buyback will be undertaken on a proportionate basis from all eligible shareholders, including promoters and members of the promoter group, in accordance with applicable regulations.
As per the latest available shareholding data, promoters and promoter group entities hold a 51.82% stake in the company.
The board has fixed 17 April 2026 as the record date to determine the eligibility of shareholders entitled to participate in the buyback.
The company also constituted a buyback committee to oversee and execute the process. It noted that the buyback price may be increased and the number of shares reduced, subject to regulatory provisions, without altering the overall buyback size.
Further details, including timelines and the offer process, will be released in due course as part of the public announcement and letter of offer.
Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.
The company’s consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.
Shares of Aurobindo Pharma were currently down 0.26% to Rs 1,332.45.
Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, has launched Pomalidomide Capsules, 1 mg, 2 mg, 3 mg and 4 mg, in the US market. The product is the generic equivalent of Pomalyst® Capsules, 1 mg, 2 mg, 3 mg and 4 mg, of BMS Pharmaceuticals Corp.
Eugia Pharma Specialities was one of the First-to-File (FTF) ANDA applicants for this product. The product will be manufactured at Eugia Unit-I.
According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S.
Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone (and sometimes bortezomib) to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.
Pomalidomide, a third-generation immunomodulatory drug (IMiD), is used in combination with dexamethasone, and sometimes bortezomib, for relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.
Shares of Aurobindo Pharma shed 0.95% to Rs 1,199.85 on the BSE.
The company confirmed there is no impact on its financials or operations due to the inspection. Aurobindo Pharma stated its commitment to maintaining high-quality manufacturing standards across all its facilities worldwide and said it will update the stock exchanges if there is any further information.
Shares of Aurobindo Pharma shed 0.04% to end at Rs 1,221.55 on the BSE on Friday.